Study Of GW823093 In Japanese Subjects With Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
2006-06-28
Target enrollment:
Participant gender:
Summary
To investigate the preliminary pharmacokinetics, pharmacodynamics, safety and tolerability of
GW823093 at doses of 15mg and 30mg given once daily for 7 days in Japanese Type 2 diabetes
mellitus (T2DM) patients.